2001
DOI: 10.1117/12.428048
|View full text |Cite
|
Sign up to set email alerts
|

<title>Computer-aided detection of lung cancer on chest radiographs: algorithm performance vs. radiologists' performance by size of cancer</title>

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
4
1

Year Published

2004
2004
2020
2020

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 10 publications
(5 citation statements)
references
References 0 publications
0
4
1
Order By: Relevance
“…A common digital image database is useful for evaluating the performances among the different CAD systems. Although we achieved a detection sensitivity of 73% with an average of 4.0 false-positive detections per image in this study, our results cannot be compared directly with those obtained in other previous reports because of the differences in the database [9][10][11]. Additional studies seem to be needed to further validate the performance of our CAD system, comparing it with other systems.…”
Section: Discussioncontrasting
confidence: 54%
See 1 more Smart Citation
“…A common digital image database is useful for evaluating the performances among the different CAD systems. Although we achieved a detection sensitivity of 73% with an average of 4.0 false-positive detections per image in this study, our results cannot be compared directly with those obtained in other previous reports because of the differences in the database [9][10][11]. Additional studies seem to be needed to further validate the performance of our CAD system, comparing it with other systems.…”
Section: Discussioncontrasting
confidence: 54%
“…However, the CAD systems used in previous studies were laboratory products. On July 2001, the United States Food and Drug Administration (FDA) approved RapidScreen RS-2000 (DEUS Technologies, Rockville, MD) for marketing as a device that assists in the detection of early-stage lung cancer [9][10][11]. This approval marked the first time that the FDA sanctioned the marketing of a device specifically targeted for the detection of lung nodules.…”
mentioning
confidence: 99%
“…As we have previously reported [1], each radiologist identifies a somewhat different group of cancers without using CAD. A CAD system identifies a specific group of cancers in each database that we can expect will overlap each radiologist's unaided detections to different degrees and on different cases; this will result in differences in the potential benefit available to each radiologist when using CAD (Chart 1).…”
Section: Discussionmentioning
confidence: 91%
“…The first commercial system for lung nodule detection CAD was developed by Deus Technology Inc. ͑Riverain Medical at present͒ and received FDA approval for clinical use in 2001. With this commercial CAD system, Freedman et al 22 reported a sensitivity of 65.0% with 5.3 false positives per image from a clinical trial in an independent validation test by use of 80 cases containing small primary lung cancers and 160 cases not containing cancers. Kakeda et al 23 reported the use of another commercial CAD system developed by Mitsubishi Space Software for the detection of lung nodules: the performance of this CAD system indicated a sensitivity of 73.0% with 4.0 false positives per image for 274 chest radiographs including 323 lung nodules.…”
Section: Introductionmentioning
confidence: 99%